Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Sorrento Therapeutics (SRNE) Stock Price
News articles about Sorrento Therapeutics (NASDAQ:SRNE) have trended somewhat positive this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sorrento Therapeutics earned a media sentiment score of 0.04 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.3975620684373 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- ETFs with exposure to Sorrento Therapeutics, Inc. : November 17, 2017 (finance.yahoo.com)
- Q1 2018 Earnings Forecast for Sorrento Therapeutics, Inc. Issued By Oppenheimer Holdings (SRNE) (americanbankingnews.com)
- Synergy Pharmaceuticals Inc. (SGYP) registers a price change of -16.80% while Sorrento Therapeutics, Inc. (SRNE … – Stocks Gallery (stocksgallery.com)
- Sorrento Therapeutics (SRNE) Subsidiary Files MAA For ZTlido – StreetInsider.com (streetinsider.com)
Several brokerages recently commented on SRNE. Oppenheimer Holdings, Inc. set a $6.00 price objective on shares of Sorrento Therapeutics and gave the company a “buy” rating in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Sorrento Therapeutics in a research note on Monday, September 18th. Roth Capital began coverage on shares of Sorrento Therapeutics in a research note on Thursday, August 3rd. They set a “buy” rating and a $7.00 price objective for the company. Finally, UBS AG began coverage on shares of Sorrento Therapeutics in a research note on Thursday, August 3rd. They set an “outperform” rating and a $7.00 price objective for the company. Six research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus price target of $11.50.
Shares of Sorrento Therapeutics (SRNE) traded up $0.05 during trading hours on Friday, reaching $2.45. 497,648 shares of the company traded hands, compared to its average volume of 798,909. Sorrento Therapeutics has a 12 month low of $1.50 and a 12 month high of $6.38. The company has a debt-to-equity ratio of 0.18, a current ratio of 0.54 and a quick ratio of 0.54.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Sorrento Therapeutics (SRNE) Stock Price” was published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-sorrento-therapeutics-srne-stock-price/1714441.html.
About Sorrento Therapeutics
Sorrento Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases.
Receive News & Ratings for Sorrento Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.